Thousands of patients who took Wegovy and developed gastroparesis””a debilitating condition where the stomach cannot empty properly””are now pursuing legal action against manufacturer Novo Nordisk. As of January 2026, approximately 3,063 lawsuits are pending in a consolidated Multidistrict Litigation (MDL 3094) in the Eastern District of Pennsylvania, with roughly 200 new cases being added each month. The litigation centers on claims that Novo Nordisk failed to adequately warn patients and healthcare providers about the risk of severe gastrointestinal complications, including stomach paralysis, before prescribing these GLP-1 receptor agonist medications.
To qualify for the Wegovy stomach paralysis lawsuit, plaintiffs generally must demonstrate they took the medication, developed gastroparesis or another severe gastrointestinal injury, and required at least one overnight hospital stay while using the drug or within six months of discontinuing it. For example, a patient who took Wegovy for weight management and subsequently experienced persistent vomiting, abdominal pain, and was diagnosed with delayed gastric emptying through a gastric emptying study would likely meet the threshold for filing a claim. This article examines the current state of the litigation, eligibility requirements, what plaintiffs can expect from the legal process, estimated settlement values, and how recent court rulings and label changes affect pending and future claims.
Table of Contents
- What Is the Wegovy Stomach Paralysis Lawsuit About?
- Who Qualifies to File a Wegovy Gastroparesis Claim?
- How the MDL Process Works for Wegovy Claims
- What Settlement Amounts Might Wegovy Plaintiffs Receive?
- Label Changes and What They Mean for the Lawsuit
- How Novo Nordisk Is Responding to the Litigation
- What to Expect Moving Forward
- Conclusion
What Is the Wegovy Stomach Paralysis Lawsuit About?
The Wegovy stomach paralysis lawsuit alleges that Novo Nordisk knew or should have known about the serious risk of gastroparesis associated with its GLP-1 medications but failed to provide adequate warnings to patients and prescribing physicians. Gastroparesis occurs when the stomach muscles stop working properly, preventing normal food digestion and movement into the small intestine. Symptoms include severe nausea, vomiting, bloating, abdominal pain, and malnutrition””conditions that can persist long after patients stop taking the medication. According to data from the federal litigation, 75 percent of the lawsuits filed allege gastroparesis as the primary injury. Another 18 percent claim ileus (impaired bowel function), 18 percent allege intestinal obstructions, and 8 percent involve gallbladder injuries.
These percentages overlap because many plaintiffs experienced multiple complications. Consider a plaintiff who initially developed gastroparesis but later required surgery for intestinal obstruction””such cases illustrate why many claims involve overlapping injury categories. The first Wegovy-related lawsuit was filed on August 2, 2023. By February 2024, the Judicial Panel on Multidistrict Litigation consolidated federal cases into MDL 3094, assigning them to Judge Karen Spencer Marston in the Eastern District of Pennsylvania. Since then, roughly 4,400 patients have filed lawsuits against GLP-1 drugmakers including Novo Nordisk, making this one of the more rapidly growing pharmaceutical litigations in recent years.
Who Qualifies to File a Wegovy Gastroparesis Claim?
Not everyone who experienced side effects while taking Wegovy will qualify for the lawsuit. Courts and law firms handling these cases have established specific eligibility criteria that potential plaintiffs must meet. According to current requirements, claimants must have taken Wegovy, suffered gastroparesis, persistent vomiting, ileus, or other severe gastrointestinal injuries, and required at least one overnight hospital stay while on the drug or within six months of stopping. A critical ruling issued by Judge Marston on August 19, 2025, further narrowed eligibility.
Plaintiffs must now demonstrate they had a gastric emptying study with results confirming delayed gastric emptying at the time of diagnosis. This means individuals who received a gastroparesis diagnosis based solely on clinical symptoms without objective testing may face challenges in the litigation. However, if you experienced severe symptoms and were diagnosed clinically but never underwent a gastric emptying study, some attorneys may still evaluate your case to determine whether additional medical documentation supports your claim. The hospitalization requirement exists to distinguish between cases involving common, expected side effects””such as temporary nausea during the initial weeks of treatment””and genuine severe injuries requiring medical intervention. Patients who managed symptoms at home without hospitalization will generally not meet the current threshold, though this could change as litigation evolves.
How the MDL Process Works for Wegovy Claims
Multidistrict Litigation consolidates similar federal lawsuits before a single judge for pretrial proceedings, including discovery, depositions, and motion practice. This structure promotes efficiency by preventing redundant proceedings across dozens of federal courts. MDL 3094, created in February 2024, centralizes all federal Wegovy and Ozempic gastroparesis claims in Philadelphia under Judge Karen Spencer Marston. The MDL process typically involves selecting a small number of representative cases””called bellwether trials””to test legal theories and provide both sides with insight into how juries might respond to the evidence. Bellwether trials for the Wegovy litigation are expected to begin in early 2026, though specific dates have not been scheduled as of January 2026.
These initial trials often influence settlement negotiations, as outcomes reveal the strength of plaintiffs’ arguments and potential damages juries might award. For example, if early bellwether verdicts favor plaintiffs with substantial damage awards, Novo Nordisk may become more inclined to negotiate global settlements. Conversely, defense victories could embolden the company to continue fighting individual claims. Plaintiffs should understand that MDL proceedings can take years, and bellwether outcomes””while informative””do not automatically determine results for all cases. Each claim ultimately rises or falls on its individual facts, including the strength of medical documentation and the plaintiff’s specific circumstances.
What Settlement Amounts Might Wegovy Plaintiffs Receive?
No settlements have been reached in the Wegovy stomach paralysis litigation as of January 2026, making any projections speculative. However, attorneys handling these cases estimate that serious injury settlements may range from $400,000 to $700,000 per case, depending on the severity of harm, length of hospitalization, ongoing medical needs, and impact on quality of life. These figures represent estimates for significant claims involving documented gastroparesis with hospitalization, not minor or temporary side effects. Plaintiffs with permanent digestive damage requiring ongoing treatment, feeding tubes, or surgical intervention would likely fall toward the higher end of settlement ranges.
Those with less severe injuries that resolved after discontinuing the medication might receive substantially lower amounts””if they qualify at all. The comparison to other pharmaceutical litigations provides some context. Settlements in similar cases involving failure-to-warn claims for serious gastrointestinal injuries have historically varied widely, from tens of thousands to over a million dollars for the most catastrophic outcomes. However, each litigation is unique, and Novo Nordisk’s litigation strategy, the outcomes of bellwether trials, and the total number of qualified plaintiffs will all influence ultimate settlement values.
Label Changes and What They Mean for the Lawsuit
Recent label updates represent a significant development in the litigation. In October 2025, Novo Nordisk added warnings about serious gastrointestinal complications””including intestinal obstruction and severe constipation””to Wegovy’s label. Earlier, in January 2025, the Ozempic label was updated to state the drug is “not recommended in patients with severe gastroparesis.” These label changes matter for several reasons. Plaintiffs’ attorneys argue they constitute an implicit acknowledgment that the risks were more serious than previously disclosed.
For claims arising before these updates, the changes support arguments that earlier warnings were inadequate. However, if you began taking Wegovy after October 2025 and the updated warnings were available, proving that you received inadequate warning becomes more complicated””though not impossible, particularly if your prescriber was not made aware of the updated risks. The timing of label changes also affects how courts view Novo Nordisk’s knowledge of the risks. If internal documents reveal the company knew about gastroparesis risks years before updating labels, this could support claims of negligence or intentional concealment. Discovery in the MDL will likely explore when Novo Nordisk became aware of these risks and whether the company delayed appropriate warnings.
How Novo Nordisk Is Responding to the Litigation
Novo Nordisk has stated publicly that the claims against it are “unfounded” and that it will “vigorously defend” the safety of its GLP-1 medications. The company continues to maintain that Wegovy and similar drugs are safe when used as directed and that known side effects are adequately disclosed in product labeling. This defensive posture is typical in pharmaceutical litigation during early stages.
Companies rarely acknowledge potential liability before bellwether trials establish how juries might respond to evidence. For plaintiffs, this means the litigation will likely continue for years before any global settlement is negotiated””if settlement occurs at all. Some pharmaceutical litigations have proceeded through extensive trials before resolution, while others settled relatively quickly after bellwether results demonstrated plaintiff-favorable trends.
What to Expect Moving Forward
The Wegovy litigation continues to grow, with new cases added monthly and bellwether trials anticipated in early 2026. A separate MDL addressing NAION (non-arteritic anterior ischemic optic neuropathy, a form of vision loss) allegedly caused by GLP-1 medications was created in December 2025, indicating the scope of claims against these drugs continues to expand beyond gastrointestinal injuries.
For individuals considering whether to file a claim, the window remains open. Consulting with an attorney experienced in pharmaceutical litigation can help determine whether your specific circumstances meet current eligibility requirements. Those who have already filed should expect a multi-year process, with resolution likely depending on bellwether trial outcomes and subsequent settlement negotiations.
Conclusion
The Wegovy stomach paralysis lawsuit represents a significant mass tort action involving over 3,000 pending federal claims and thousands of additional plaintiffs in state courts. Eligible claimants must demonstrate they took Wegovy, developed gastroparesis or another severe gastrointestinal condition confirmed by appropriate medical testing, and required hospitalization.
While no settlements have been finalized, attorneys estimate serious injury cases could resolve in the $400,000 to $700,000 range. Patients who believe they were harmed by Wegovy should gather medical records documenting their diagnosis and treatment, particularly gastric emptying study results, hospitalization records, and documentation linking their condition to medication use. With bellwether trials expected in early 2026, the coming year will be pivotal in determining how this litigation unfolds and what relief plaintiffs may ultimately receive.